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Current understanding of resistance and susceptibility to vulvovaginal candidiasis challenges
existing paradigms of host defence against fungal infection. While abiotic biofilm formation has a
clearly established role during systemic Candida infections, it is not known whether C. albicans
forms biofilms on the vaginal mucosa and the possible role of biofilms in disease. In vivo and ex
vivo murine vaginitis models were employed to examine biofilm formation by scanning electron
and confocal microscopy. C. albicans strains included 3153A (lab strain), DAY185 (parental
control strain), and mutants defective in morphogenesis and/or biofilm formation in vitro (efg1/
efg1 and bcr1/bcr1). Both 3153A and DAY815 formed biofilms on the vaginal mucosa in vivo and
ex vivo as indicated by high fungal burden and microscopic analysis demonstrating typical biofilm
architecture and presence of extracellular matrix (ECM) co-localized with the presence of fungi. In
contrast, efg1/efg1 and bcr1/bcr1 mutant strains exhibited weak or no biofilm formation/ECM
production in both models compared to wild-type strains and complemented mutants despite
comparable colonization levels. These data show for the first time that C. albicans forms biofilms
in vivo on vaginal epithelium, and that in vivo biotic biofilm formation requires regulators of biofilm
formation (BCR1) and morphogenesis (EFG1).
INTRODUCTION
Vulvovaginal candidiasis (VVC) affects 75% of all women
at least once in their lifetime (Sobel et al., 1998), most often
during childbearing years (Sobel, 1992). Another smaller
group of women (5–8%) experience recurrent vulvova-
ginal candidiasis (RVVC), defined as having three or more
episodes per year (Sobel, 1992). Although several Candida
species have been implicated in VVC and RVVC, Candida
albicans is the predominant aetiological agent, causing 85–
95% of these infections (Sobel et al., 1998).
Current understanding of resistance and susceptibility to
VVC challenges existing paradigms of host defence against
fungal infection. Although the adaptive immune response
plays a major role in protection against oral and
gastrointestinal mucosal Candida infections, the innate
immune response plays a more prominent role in VVC. In
resistant women, vaginal epithelial cells are important for
protection against infection (Fidel et al., 2004). In
susceptible women, symptomatic VVC is associated with
an aggressive neutrophil migration into the vagina and
subsequent inflammatory response initiated by the inter-
action of C. albicans with vaginal epithelial cells (Barousse
et al., 2001, 2005). This inflammatory response is not
protective, but instead appears to be a major cause of the
symptoms associated with infection.
Recently there has been tremendous interest in the role of
biofilms in infectious diseases. It is estimated that 80% of
human infections result from pathogenic biofilms (NIH,
1999). Biofilms are communities of micro-organisms that
are embedded in an extracellular matrix (ECM), forming a
complex three-dimensional architecture. Candida biofilm
development on abiotic surfaces can be divided into several
growth stages, including early, intermediate and mature
(Chandra et al., 2001). During early biofilm formation,
yeast cells adhere to an appropriate surface and initiate
germ tube formation. The intermediate phase is character-
ized by continued hyphal elongation and production of
ECM, which consists of cell wall polysaccharides and
protein (Baillie & Douglas, 2000). Mature biofilms consist
Abbreviations: CM, confocal microscopy; ConA-TR, concanavalin A–
Texas red conjugate; ECM, extracellular matrix; (R)VVC, (recurrent)
vulvovaginal candidiasis; SEM, scanning electron microscopy.
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extending away from the surface. Newly formed daughter
yeast cells grow out of hyphal elements and are released,
seeding new niches for biofilm formation or infection.
Moreover, biofilm formation is dependent on the ability to
undergo morphogenesis; mutants defective in hyphal
formation in vitro are also defective in biofilm formation
(Nobile et al., 2006b; Ramage et al., 2002).
Candida biofilms have been studied primarily on abiotic
surfaces (reviewed by Blankenship & Mitchell, 2006;
Ramage et al., 2006). Significant attention has been given
to Candida biofilm formation of indwelling catheters,
which can lead to life-threatening systemic infections
(Crump & Collignon, 2000; Dominic et al., 2007; Kojic &
Darouiche, 2004). More recently, biofilm formation on
biotic surfaces has received some attention; C. albicans was
shown to form biofilms on oral mucosa in an immuno-
suppressed murine model of oropharyngeal candidiasis
(Dongari-Bagtzoglou et al., 2009). However, in VCC and
RVVC it is unknown whether C. albicans exist as biofilms
on the vaginal mucosa and, if so, whether the biofilms play
a role in the immunopathogenesis.
The purpose of this study was to determine whether
Candida forms biofilm on vaginal mucosa, using both an in
vivo and a novel ex vivo model. Biofilm-defective C.
albicans mutants were also used to define specific para-
meters of biofilm formation associated with the tissue.
METHODS
Candida albicans strains and handling. C. albicans strains used in
this study are listed in Table 1. Wild-type (WT) strains included
3153A (lab strain) and DAY185 (parent strain). Strain DAY185 is a
complemented prototroph derived from a triple auxotrophic strain
(BWP17; parent, SC5314), which is frequently used to produce
knockout and complemented strains of C. albicans. Strains HLC52
(efg1/efg1) and HLC74 (efg1/efg1+pEFG1) were a gift from G. R. Fink
(Whitehead Institute, Cambridge, MA, USA). Strains CJN702 (bcr1/
bcr1) and CJN698 (bcr1/bcr1+pBCR1) were a gift from A. P. Mitchell
(Carnegie Mellon University, Pittsburgh, PA, USA). For each
experiment, strains were subcultured from freezer stocks onto
Sabouraud dextrose agar (SDA) plates and incubated at 30 uC
overnight. Cultures were washed in 16 PBS, counted, and diluted in
16 PBS for inoculation.
Mouse strains. Female C57BL/6 or CBA/J mice, 6–8 weeks of age
(Charles River and NIH) were used in this study. All mice were
maintained at an American Association for the Accreditation of
Laboratory Animal Care-accredited animal facility at Wayne State
University (WSU) or Louisiana State University Health Sciences
Center (LSUHSC) and housed in accordance with the procedures
outlined in the Guide for the Care and Use of Laboratory Animals
under an animal study proposal approved by the WSU animal
investigation committee and the LSUHSC Institutional Animal Care
and Use Committee (IACUC).
In vivo model. Mice were administered 0.1 mg 17-b-oestradiol
(Sigma-Aldrich) in 0.1 ml sesame seed oil (Sigma-Aldrich) sub-
cutaneously 3 days prior to inoculation. They were inoculated
intravaginally with 20 ml C. albicans 3153A (2.5610
6 ml
21),
DAY185 (2.5610
8 ml
21) or biofilm mutants (2.5610
8 ml
21).
Higher inocula were used for DAY185 and mutants because initial
experiments demonstrated that 3153A colonizes mucosal tissue better
than DAY185 and biofilm mutants, as previously reported (Naglik
et al., 2008; Taylor et al., 2000). At specified time points, mice were
euthanized and their vaginae were excised and cut longitudinally to
expose the mucosal surface. The vaginae were then bisected; half the
tissue was used to determine fungal load by quantitative plate count
and the other half was used for confocal microscopy or scanning
electron microscopy.
Ex vivo model. Mice were treated with oestrogen as described above
3 days prior to vaginal harvest. On experimental days, mice were
euthanized and their vaginae were excised and cut longitudinally to
expose the mucosal surface. The vaginae were placed with the
mucosal side facing up in 6-well tissue culture treated plates with
500 ml PBS (16), which results in the vaginal mucosal surface being
exposed and unsubmerged. Penicillin-streptomycin (16, MP Bio-
medicals) was added to the PBS to prevent growth of normal vaginal
bacteria. C. albicans isolates (1610
6 blastoconidia) were added to the
mucosal surface in 0.1 ml PBS and incubated at 37 uC with CO2. The
inoculum was based on preliminary studies that revealed optimal
colonization for microscopic evaluations. Tissues were removed from
the incubator at specified time points and bisected but were not
washed prior to analysis. Half the tissue was used to determine fungal
load and the other half was used for microscopy.
C.f.u. counts. Following harvest, vaginae were placed in 5 ml sterile
tubes with 1 ml sterile H2O. Tissues were weighed and homogenized,
and 10-fold dilutions were prepared and plated to SDA with
ampicillin and erythromycin to prevent the growth of normal vaginal
Table 1. Strains used in this study
Strain Genotype Source
3153A Wild-type Slutsky et al. (1985)
DAY185 ura3D::imm434/ura3D::imm434 HIS1::his1::hisG/his1::hisG ARG4::URA3::arg4::hisG/
arg4::hisG
Norice et al. (2007)
HLC52 ura3D::imm434/ura3D::imm434 efg1::hisG/efg1::hisG-URA3-hisG Lo et al. (1997)
HLC74 ura3D::imm434/ura3D::imm434 efg1::hisG/efg1::hisG LEU2/LEU2:pEFG1-URA3-LEU2 Lo et al. (1997)
CJN702 ura3D::imm434/ura3D::imm434 arg4::hisG/arg4::hisG his1::hisG::pHIS1/his1::hisG bcr1::
ARG4/bcr1::URA3
Nobile & Mitchell (2005)
CJN698 ura3D::imm434/ura3D::imm434 arg4::hisG/arg4::hisG his1::hisG::pHIS1-BCR1/his1::hisG
bcr1::ARG4/bcr1::URA3
Nobile & Mitchell (2005)
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counted and log c.f.u. ml
21 and log c.f.u. (g tissue)
21 were calculated.
Confocal microscopy (CM). Excised vaginal tissue was placed in 12-
well dishes and stained with 1 mg ml
21 Calcofluor White (Fluka) to
visualize yeast and hyphae and 50 mgm l
21 concanavalin A–Texas red
conjugate (ConA-TR, Molecular Probes) to stain the biofilm ECM for
20 min at room temperature. No prior washing or sectioning of tissue
was performed. Vaginal tissues were removed from staining wells,
gently rinsed with 16 PBS to remove exogenous stain, and placed
epithelial side up onto glass microscope slides. Vaginal tissues were
covered with a glass coverslip and slides were examined under oil
immersion with a Nikon Eclipse E800 microscope with Metamorph
software.
Scanning electron microscopy (SEM). Vaginal tissue was placed in
10% formalin. Tissues were dehydrated in 20% ethanol for 1 min,
followed by three successive 1 min incubations in 40%, 60%, 80%,
95% and 100% ethanol, and finally by three successive 1 min
incubations in acetone. Dried samples were affixed to SEM stubs and
placed into a gold/palladium sputter coater. Specimens were viewed at
300–20006 magnification in a Hitachi S-2700 scanning electron
microscope (LSUHSC Imaging Core) with the voltage set to 15 kV.
Statistical analysis. Statistical analysis of the data was conducted
using Prism software (GraphPad). Data were analysed by ANOVA
(analysis of variance) followed by Dunnett’s multiple comparison test.
Significance was defined as P,0.05.
RESULTS
C. albicans forms in vivo and ex vivo biofilms on
vaginal mucosae
To initially determine whether C. albicans forms biofilms
on vaginal mucosae, we used both in vivo and ex vivo
colonization models using WT strain 3153A. For the in vivo
model, vaginal tissue was analysed 48 h post-inoculation
for biofilm formation by scanning election microscopy
(SEM) and confocal microscopy (CM). This is a commonly
used early time point to monitor colonization during
experimental vaginitis. SEM analysis revealed fungal
colonization and the presence of a complex network of
both yeast and hyphae, and ECM accumulation both in
vivo and ex vivo (Fig. 1a, b). CM analysis confirmed that
biofilm ECM was present, as demonstrated by the bright
red cell-associated staining and the hazy diffuse red
material covering the hyphae (Fig. 1d).
We also examined ex vivo biofilm formation on vaginal
explants at 48 h post-inoculation, which is a time point
correlating with development of mature biofilm in vitro
(Chandra et al., 2001). Ex vivo model biofilms were pheno-
typically similar to vivo biofilms. At 48 h, a characteristic
biofilm was visible by SEM, consisting of yeast and hyphae
surrounded by ECM (Fig. 1b). Biofilm ECM was also
evident by CM, both cell associated and interspersed
between the hyphae (Fig. 1e). No Candida colonization was
observed in control uninoculated vaginal epithelium, either
in vivo or ex vivo (Fig. 1c, f and data not shown). It is
important to note that although ConA-TR stains epithelial
cells, the fluorescence intensity was weaker and exposure
time was increased to visualize epithelial cells compared to
ConA-TR-stained ECM material (Fig. 1d, e). The presence
of c.f.u. following the plating of tissue homogenates under
in vivo or ex vivo conditions confirmed the presence of
viable C. albicans.
Kinetics of vaginal mucosal biofilm formation
We next examined the kinetics of biofilm development in
both models by SEM, CM and quantitative plate count
analysis. Vaginae were harvested at 8, 24, 48 and 72 h post-
inoculation with C. albicans 3153A. Half the tissue was
processed for scanning SEM or CM and the other half was
used to determine fungal load (c.f.u.). For the in vivo
model, yeast had initiated germination on the vaginal
epithelium (SEM) by 8 h post-inoculation, with little or no
ECM (CM) (Fig. 2). At 24 h the initial layer of yeast was
evident under the elongating hyphae. Also, a small amount
of ECM material was visible, as demonstrated by the diffuse
red staining in the CM. At 48 h, the biofilm was more
extensive and ECM appeared thicker and covered some of
the cellular portion of the biofilmas revealed by SEM and
CM (Fig. 2, red staining). By 72 h, ECM accumulation was
more uniform by SEM, appearing as a smooth coat on top
of the fungal biofilm. By CM, ECM staining appeared cell-
associated and also more diffuse, lying above the cellular
portion of the biofilm. The pattern of colonization with the
biofilm was not confluent over all of the vaginal tissue, but
did form patches of thicker and thinner biofilms spread
over the tissue (data not shown). Fungal burden also increased
steadily with time, starting at #10
3 c.f.u. (g tissue)
21 at 2 h
and increasing to #10
5 c.f.u. (g tissue)
21 by 72 h (Fig. 3a).
Maximal fungal burden was observed by 72 h; however, very
little change was observed between 48 and 72 h.
For the ex vivo model, considerable yeast had germinated
on the vaginal mucosa by 8 h, with little ECM present
(CM) and the mucosal surface could be seen under the
hyphae (SEM) (Fig. 2). At 24 h, a hyphal network was
formed (SEM) and biofilm ECM was evident (CM, red
staining). By 48 h, the biofilm was significantly denser than
at 24 h and ECM appeared more prevalent (SEM). At 72 h,
yeast forms (CM) were evident at the apical surface of the
biofilm in conjunction with the residential hyphae, which
coincided with the predicted dispersal phase of biofilm
growth (Blankenship & Mitchell, 2006). As with in vivo
biofilms, ex vivo biofilm fungal burden steadily increased
over time, starting at #10
4 c.f.u. (g tissue)
21 at 2 h and
increasing to #10
8 c.f.u. (g tissue)
21 by 48–72 h (Fig. 3b).
Maximal fungal burden was observed by 48 h and c.f.u.
remained relatively unchanged up to 72 h.
Role of morphogenesis regulator EFG1 and
biofilm regulator BCR1
To determine requirements for biofilm formation on
vaginal tissue and whether biofilm formation was required
for vaginal colonization, we evaluated C. albicans mutant
Candida albicans vaginal biofilms
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morphogenesis (efg1/efg1) and biofilm formation (bcr1/
bcr1) and complemented mutants in the in vivo and ex vivo
models. These mutants have previously been shown to
form poor or no biofilms on abiotic surfaces (Nobile et al.,
2006a, b; Nobile & Mitchell, 2005; Ramage et al., 2002). For
the in vivo model, we chose to examine biofilm mutants at
72 h, the time at which mature biofilms are evident with
wild-type strains. Microscopic evaluation demonstrated
that in vivo biofilms of strain DAY185 (parental control
strain) were similar in appearance to 3153A biofilms at
72 h (Fig. 4a). Similar results were observed with the wild-
type strain SC5314, which is the parent of control strain
DAY185 (data not shown). This also confirms that the
URA3 marker did not affect vaginal colonization levels, as
SC5314 contains URA3 at the native locus and DAY185
contains URA3 at a non-native locus. Yeast and hyphae
were present and ECM was evident, as indicated by the
smooth covering overlying the cells in the SEM image and
diffuse red (ConA-TR) staining overlying the cells in the
CM image. In contrast, the efg1/efg1 mutant produced only
yeast and pseudohyphal forms, and no ECM was detected
by CM, as indicated by the lack of diffuse ConA-TR
staining, although staining of underlying epithelial cells was
evident. The efg1/efg1 mutant was not detectable by SEM,
possibly due to the inability of this strain to remain
attached to the epithelium during the tissue-processing
procedure. Biofilm formation was restored in the com-
plemented strain efg1/efg1+pEFG1 to levels similar to
those of the WT strain. Despite the lack of biofilm
formation in vivo, the efg1/efg1 mutant strain exhibited
colonization levels that were not significantly different
from the parental control strain or the complemented
mutant (Fig. 4b).
BCR1 is a transcriptional regulator that is required for
biofilm formation on abiotic surfaces in vitro and in vivo,
forming thin weakly adherent biofilms composed of yeast
and hyphae, but with little ECM production (Nobile et al.,
2006a; Nobile & Mitchell, 2005). During vaginal in vivo
biofilm formation the bcr1/bcr1 mutant was also able to
produce some hyphae but very little ECM was visible by
SEM, which is evident by the lack of smoothness and the
clarity of the cell shape. The ability to form a vigorous
biofilm with substantial ECM production was restored in
the complemented mutant (bcr1/bcr1+pBCR1). In fact
Fig. 1. Establishment of vaginal mucosal biofilm. (a, d) For the in vivo model, mice were administered oestrogen and intravaginally
inoculated with C. albicans 3153A (510
4 blastoconidia). At 48 h post-inoculation, vaginae were excised and the tissue was
processed for SEM or CM. For CM, vaginae were stained with calcoflour white (blue) to visualize yeast/hyphae, and with ConA-
TR to visualize biofilm ECM. (b, e) For the ex vivo model, mice were administered oestrogen and vaginae were harvested at 48 h
post-inoculation. Tissues were inoculated with C. albicans 3153A (10
6 blastoconidia). At 48 h post-inoculation, vaginae were
bisected and processed for SEM or CM and confirmation of fungal burden. (c, f) In vivo control tissues were uninoculated. SEM
images were taken at 1000 magnification, and CM images at 600 magnification. The figure shows representative images of
areas of biofilm growth from three independent repeats; n54 mice or vaginal explants per time point.
M. M. Harriott and others
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production by the complemented strain. Again, there was
no significant difference in colonization levels with the
bcr1/bcr1 mutant strain compared with the parental and
complemented strains (Fig. 4b).
For the ex vivo model, oestrogenized vaginal explants were
inoculated with the same isolates and incubated for 48 h,
the earliest time point for mature biofilm formation by
wild-type strains. Microscopic examination demonstrated
that the WT parent strain DAY185 formed biofilms ex vivo
similar to 3153A (Fig. 5a). Similar results were observed
with the wild-type strain SC5314, which is the parent of
control strain DAY185 (data not shown). An extensive
hyphal network was present with significant ECM, as
indicated by the smooth covering overlying the cells in the
SEM image and diffuse red staining (ConA-TR) overlying
the calcofluor-white-stained fungal cells in the CM image.
The efg1/efg1 mutant colonized and produced yeast and
pseudohyphal forms at 48 h with no ECM present (SEM).
In contrast to DAY185, there was a lack of diffuse ConA-
TR staining with the efg1/efg1 mutant by CM, indicating a
lack of ECM. Similar to the in vivo model, very few
organisms were visible by SEM. Interestingly, the com-
plemented mutant was unable to produce significant
amounts of hyphae ex vivo, but still was able to produce
ECM visible by CM and SEM. The bcr1/bcr1 mutant
produced both yeast and a few hyphae, but no ECM was
Fig. 2. Microscopic analysis of vaginal mucosal biofilm formation in vivo and ex vivo. For the in vivo model, mice were
administered oestrogen and intravaginally inoculated with C. albicans 3153A (510
4 blastoconidia), and vaginae were
harvested at 8, 24, 48 and 72 h. For the ex vivo model, mice were administered oestrogen and vaginae were harvested and
inoculated with C. albicans 3153A (10
6 blastoconidia) and incubated for 8, 24, 48, or 72 h. Tissues were bisected and
processed for SEM, CM or fungal burden (Fig. 3). SEM images were taken at 1000 magnification, and CM images at 600
magnification. The figure shows representative images of areas of biofilm growth from three independent repeats, n54 mice or
vaginal explants per time point.
Candida albicans vaginal biofilms
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which showed a lack of diffuse ConA-TR staining, although
underlying lightly stained epithelial cells could be seen
(Fig. 5a). In contrast, ECM production was restored in the
complemented mutant. However, no differences in col-
onization were observed between WT strain DAY185,
mutants, or complemented mutants (Fig. 5b).
DISCUSSION
Biofilms are present ubiquitously and have established a
unique niche on abiotic and biotic surfaces. To our
knowledge this is the first report of an in vivo fungal
mucosal biofilm in an immunocompetent animal model of
vaginitis. Prior to this study, the only in vivo vaginal
biofilm characterized was bacterial, consisting of
Gardnerella vaginalis (Scott et al., 1989; Swidsinski et al.,
2008; van der Meijden et al., 1988). In this study, we
demonstrate by microscopic analysis that C. albicans
biofilms are present on the vaginal mucosa. C. albicans
vaginal biofilms have biofilm architecture typical of in
vitro-grown C. albicans biofilms, consisting of yeast and
hyphae forming a complex network surrounded by ECM
(Chandra et al., 2001; Ramage et al., 2001). ECM was
evident by SEM, appearing as a thick film covering the
cellular portion of the biofilm. For CM analysis, we used
ConA-TR staining to visualize ECM. ConA is a lectin that
binds to C. albicans polysaccharides secreted as part of the
matrix. b-Glucan is a cell wall polysaccharide that has been
detected in Candida ECM by a Limulus amoebocyte lysate
clotting enzyme based assay (Nett et al., 2007a, b).
However, a monoclonal b-glucan antibody, which stains
the cell wall or cell-associated matrix, was unable to stain
the non-cell-associated ECM that is interspersed between
the cells (Dongari-Bagtzoglou et al., 2009). In this same
study, ConA staining effectively stained the interspersed
ECM, and it has been used by many investigators to
visualize Candida biofilm matrix (Chandra et al., 2001;
Dongari-Bagtzoglou et al., 2009; Nobile & Mitchell, 2005).
Therefore, our observations satisfy the definition of a
biofilm and provide evidence for the presence of biofilm on
the vaginal mucosa. In addition to the in vivo model, we
developed an ex vivo model using vaginal explants, which
were kept in a moist controlled environment. Although no
exogenous nutrients were provided, C. albicans was able to
adhere, and to form hyphae and subsequent biofilms
encased in ECM on vaginal explants. The ability to form a
biofilm in the absence of exogenous growth media
demonstrates that growth occurs most likely by scavenging
host nutrients.
Kinetics studies showed that in vivo and ex vivo biofilm
formation followed closely with increases in fungal burden.
Although the c.f.u. assay may under-represent the actual
cell numbers, due to the presence of hyphae in the biofilm,
we obtained consistent measurements using this method.
One caveat is that testing mutants with defects in
morphogenesis could affect the c.f.u. levels relative to a
wild-type strain. However, systemic infection models
routinely use the c.f.u. assay to assess tissue fungal burden
in vivo. One way to address this is to use an alternative
assay for fungal burden such as a chitin assay to confirm
results from the c.f.u. assay. Our results are also consistent
with the kinetics of in vitro biofilms grown on silicone
discs, which show steady increases in dry weight measure-
ments until 36–48 h and then remain stationary (Chandra
et al., 2001; Hawser & Douglas, 1994). In addition, the
SEM and CM results for both models progressively showed
evidence of ECM. The in vivo and ex vivo vaginal biofilm
development phases closely resemble those of in vitro
biofilms (Chandra et al., 2001; Ramage et al., 2001). In vitro
biofilms on abiotic surfaces have distinct developmental
phases: the early phase (#0–11 h), in which adhesion and
morphogenesis occurs; the intermediate phase (#12–
30 h), in which the hyphae continue growth and ECM
begins to emerge; and the maturation phase (#38–72 h),
by which ECM completely surrounds the biofilm.
Interestingly, the ex vivo model had an accelerated pace
compared to the in vivo model, which could be due to
several factors. First, the ability of the whole intact tissue in
vivo to mount an antifungal response could play a role in
limiting fungal growth. Second, in vivo vaginal tissue
Fig. 3. In vivo and ex vivo kinetics of vaginal fungal burden. For the
in vivo model (a), mice were administered oestrogen and
intravaginally inoculated with C. albicans 3153A (510
4 blasto-
conidia), and vaginae were harvested at 8, 24, 48 and 74 h. For
the ex vivo model (b), mice were administered oestrogen and
vaginae were harvested and inoculated with C. albicans 3153A
(10
6 blastoconidia) and incubated for 8, 24, 48, or 72 h. Tissues
were bisected and processed for quantitative plate counts. The
same mice were used for microscopy (Fig. 2) and c.f.u. analysis.
Results represent means (±SE) of three independent repeats;
n54 mice or vaginal explants per time point.
M. M. Harriott and others
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organic acids and proteins, which maintain properties
such as pH and osmolarity (Owen & Katz, 1999). Finally,
ex vivo in a tissue-culture setting, the vaginal tissue is
completely exposed and unsubmerged in PBS containing
antibiotics, whereas intact tissue has a degree of protection
by bacterial microbiota.
To further evaluate C. albicans vaginal biofilms, we tested
several biofilm-deficient mutants in the in vivo and ex vivo
murine models. EFG1 encodes a transcriptional factor that
is required for morphogenesis under most hypha-inducing
conditions in vitro (Lo et al., 1997; Stoldt et al., 1997).
Accordingly, the efg1/efg1 mutant is unable to form
biofilms in vitro in RPMI or YNB+glucose; however, its
biofilm formation ability in vivo has not been previously
reported (Ramage et al., 2002; Watamoto et al., 2009). In
both our in vivo and ex vivo vaginal biofilm models, the
efg1/efg1 mutant is also defective in morphogenesis and
biofilm formation, lacking typical biofilm architecture and
ECM production. This observation is in agreement with
previous reports that EFG1 is required for production of
hyphae and subsequent biofilm formation in vitro (Ramage
et al., 2002). Interestingly, few or no organisms were
detectable by SEM, which requires significant sample
processing with several dehydration procedures. This
observation suggests that although colonization is detect-
able by c.f.u. analysis, these strains exhibit defects in
adhesion, and are unable to remain adherent throughout
the SEM processing procedure. The complemented mutant
was able to form a normal biofilm consisting of yeast and
hyphae and substantial ECM production in vivo similar to
WT. However, ex vivo, this strain was unable to produce
hyphae, forming a yeast-dominated biofilm with consid-
erable ECM. One explanation for this observation is that
morphogenesis-inducing signals could be stronger in vivo
than ex vivo. Another possibility is that the differences in
microenvironment that result from the way the explants
were incubated (unsubmerged and exposed to CO2) could
influence the growth of the mutants. This could lead to
differential EFG1 expression patterns in the WT strain
compared with the complemented strain ex vivo. This is
important when considering appropriate models for the
future, as well as defining what the actual signals are in vivo
which lead to biofilm formation. Although this remains to
be proven, these results also imply that Efg1 acts on two
(separable) levels during biofilm formation, i.e. ECM
production and hyphal growth.
Fig. 4. Role of EFG1 and BCR1 during in vivo vaginal biofilm formation. Mice were administered oestrogen and intravaginally
inoculated with C. albicans strain DAY185, efg1/efg1, efg1/efg1+pEFG1, bcr1/bcr1 or bcr1/bcr1+pBCR1 (510
6
blastoconidia), and vaginae were harvested at 72 h. Tissues were bisected and processed for (a) SEM or CM, or (b)
quantitative plate counts. The figure shows representative images or means (±SE) of three independent repeats; n54 mice or
vaginal explants per time point.
Candida albicans vaginal biofilms
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for production of vigorous biofilms on abiotic surfaces in
vitro and in vivo in a catheter model (Nobile et al., 2006a;
Nobile & Mitchell, 2005). The defect in biofilm formation
is likely due to a lack of proper adhesin expression on the
cell surface, but not due to a defect in morphogenesis
(Nobile et al., 2006a). In our vaginal models, the bcr1/bcr1
mutant was defective in biofilm formation both in vivo and
ex vivo, producing little or no ECM. However, the ability to
form mature biofilms in both models was restored in the
complemented strain. These results are in agreement with a
previous study that demonstrated that BCR1 is necessary
for normal biofilm development in vitro and in vivo in a rat
catheter model (Nobile et al., 2006a, b). One notable
difference is that the bcr1/bcr1 mutant formed more
hyphae and ECM under in vivo conditions compared with
ex vivo conditions. This again indicates that there may be
stronger morphogenesis-inducing signals in vivo, which
could be due to differences in the microenvironment
resulting from the incubation method for the explants.
Another issue is that while the efg1/efg1 mutant was unable
to remain attached for SEM visualization, the bcr1/bcr1
mutant was more adherent. Efg1 is upstream of Bcr1 in
relation to the regulation of genes involved in adherence
and biofilm formation. Therefore, the efg1/efg1 mutant has
additional defects, including defects in morphogenesis.
While the adhesion of these mutants has not been directly
compared on vaginal tissues, it is possible that the Efg1
regulates additional adhesins not regulated by Bcr1.
Another possible explanation is that these mutants could
result in differential induction of epithelial surface proteins
that are adhesin targets. Overall, the fact that the mutants
that are deficient in biofilm formation in vitro are also
deficient in biofilm formation in vivo and ex vivo on
vaginal mucosa supports the assertion that C. albicans
forms true biofilms in our models.
This first report of C. albicans biofilm formation on vaginal
mucosal tissue is extremely relevant as a newly characterized
biotic surface Candida biofilm in an immunocompetent
Fig. 5. Role of EFG1 and BCR1 during ex vivo vaginal biofilm formation. Mice were administered oestrogen and vaginae were
harvested and inoculated with C. albicans strains DAY185, efg1/efg1, efg1/efg1+pEFG1, bcr1/bcr1, bcr1/bcr1+pBCR1
(10
6 blastoconidia) and incubated for 48 h. Tissues were bisected and processed for (a) SEM or CM, or (b) quantitative plate
counts. The figure shows representative images or means (±SE) of three independent repeats; n54 mice or vaginal explants
per time point.
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3642 Microbiology 156host. It is unknown if Candida always exists as a mature
biofilm on mucosal surfaces, or only during times of
increased fungal burden (e.g. exacerbation of the symp-
tomatic condition during infection). This raises a series of
interesting questions: does the presence of a biofilm
determine whether C. albicans behaves as a pathogen, and
does the biofilm play a role in the host response and/or
pathogenesis of disease? Another unknown is how com-
mensal vaginal bacteria influence C. albicans mucosal
biofilm formation. Finally, with C. albicans rarely exhibiting
resistance to azoles during VVC (Bauters et al., 2002;
Mathema et al., 2001), how does this relate to the high rates
of biofilm resistance on abiotic surfaces? The in vivo and
novel ex vivo murine models employing biofilm-defective
mutants will be excellent to investigate these important
questions.
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